Home›Trial›NCT03737734
NCT03737734NAACTIVE NOT RECRUITING

Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia (DaRT)

Study Summary

A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia

Conditions
Skin CancerMucosal Neoplasm of Oral CavitySoft Tissue Neoplasm
Interventions / Drugs
Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
View on ClinicalTrials.gov ↗
Sponsor
DRTS
Alpha Tau Medical Ltd.
Biotech / Pharma
F26/100
Study Details
Enrollment30 participants
Primary Completion—
Lead SponsorAlpha Tau Medical LTD.
Data Retrieved2026-06-17 02:56:49.846164+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

This trial phase represents an early or specialized stage of clinical development.

Status & Expected Data

Enrollment is complete. The trial is in its follow-up or data collection phase — a readout may occur on or near the primary completion date.

Enrolled: 30 participants
Sponsor Catalyst Profile

Alpha Tau Medical Ltd. (DRTS) is the sponsoring company for this trial. BiotechSign currently grades this company F (26/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

DRTS Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.